Research Publications

Delta4 Research

Computational drug repositioning of clopidogrel as a novel therapeutic option for focal segmental glomerulosclerosis

Gebeshuber C, Daniel-Fischer L, Regele H, Schachner H, Aufricht C, Kornauth C, Ley M, Alper S, Herzog R, Kratochwill K, Perco P

Transl Res 2023 j.trsl.2023.04.001

Team Member Historical Research​

Lithium preserves peritoneal membrane integrity by suppressing mesothelial cell alphaB-crystallin

Herzog R, Sacnun JM, Gonzalez-Mateo G, Bartosova M, Bialas K, Wagner A, Unterwurzacher M, Sobieszek IJ, Daniel-Fischer L, Rusai K, Pascual-Anton L, Kaczirek K, Vychytil A, Schmitt CP, Lopez-Cabrera M, Alper SL, Aufricht C, and Kratochwill K

Sci Transl Med 2021 13(608):eaaz9705

Computational Drug Screening Identifies Compounds Targeting Renal Age-associated Molecular Profiles

Koppelstaetter C, Leierer J, Rudnicki M, Kerschbaum J, Kronbichler A, Melk A, Mayer G, Perco P

Comput Struct Biotechnol J 2019 17:843-853

Predictive Biomarkers for Linking Disease Pathology and Drug Effect

Mayer B, Heinzel A, Lukas A, Perco P

Curr Pharm Des 2017 23(1):29-54

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G

Diabetologia 2019 62(7):1154-1166

A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor

Licciardello MP, Ringler A, Markt P, Klepsch F, Lardeau CH, Sdelci S, Schirghuber E, Muller AC, Caldera M, Wagner A, Herzog R, Penz T, Schuster M, Boidol B, Durnberger G, Folkvaljon Y, Stattin P, Ivanov V, Colinge J, Bock C, Kratochwill K, Menche J, Bennett KL and Kubicek S

Nat Chem Biol 2017 13(7):771-778

Synthetic lethality guiding selection of drug combinations in ovarian cancer

Heinzel A, Marhold M, Mayer P, Schwarz M, Tomasich E, Lukas A, Krainer M, Perco P

PLoS One 2019 14(1):e0210859

Effects of Alanyl-Glutamine Treatment on the Peritoneal Dialysis Effluent Proteome Reveal Pathomechanism-Associated Molecular Signatures

Herzog R, Boehm M, Unterwurzacher M, Wagner A, Parapatics K, Majek P, Mueller AC, Lichtenauer A, Bennett KL, Alper SL, Vychytil A, Aufricht C and Kratochwill K

Mol Cell Proteomics 2018 17(3):516-532

Identification of dicarbonyl and L-xylulose reductase as a therapeutic target in human chronic kidney disease

Perco P, Ju W, Kerschbaum J, Leierer J, Menon R, Zhu C, Kretzler M, Mayer G, Rudnicki M; Nephrotic Syndrome Study Network (NEPTUNE)

JCI Insight 2019 4(12):e128120

Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes

Heinzel A, Kammer M, Mayer G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, Gilmour P, Wilson JM, Duffin KL, Abdalla M, McCarthy MI, Heinze G, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R; BEAt-DKD Consortium

Diabetes Care 2018 41(9):1947-1954

Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes

Kammer M, Heinzel A, Willency JA, Duffin KL, Mayer G, Simons K, Gerl MJ, Klose C, Heinze G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, McCarthy MI, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R; BEAt-DKD Consortium

Kidney Int 2019 96(6):1381-1388